Mission BioCapital
Investor profile
Venture capital
Mission BioCapital has backed 3 European tech companies across 4 funding rounds between 2022 and 2026, joining rounds totalling €221M. Most active in Healthtech. Data as of Nov 2026.
Deals
4
distinct rounds
Companies
3
backed
Active span
2022–2026
5 yrs
Total round €
€221M
sum of rounds joined
Deals by year
distinct rounds / yearMission BioCapital — deals by year — interactive chart.
Data table
| Mission BioCapital — deals by year | |
|---|---|
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 1 |
Top sectors
by dealsMission BioCapital — top sectors — interactive chart.
Data table
| Mission BioCapital — top sectors | |
|---|---|
| Healthtech | 4 |
Stages
by dealsMission BioCapital — stages — interactive chart.
Data table
| Mission BioCapital — stages | |
|---|---|
| Series A | 2 |
| Series B | 1 |
| Series C | 1 |
Countries
by dealsMission BioCapital — countries — interactive chart.
Data table
| Mission BioCapital — countries | |
|---|---|
| Switzerland | 2 |
| Denmark | 1 |
| Netherlands | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- BioMedPartners2
- GIMV2
- Pfizer Ventures2
- AbbVie Ventures1
- Catalyze Capital1
- Double Point Ventures1
- Droia Ventures1
- EIFO1
- Fiscus Financial1
- GL Capital1
- INKEF Capital1
- Innovestor Life Science Fund1
- Lightspeed Venture Partners1
- Ljungström family office1
- Modi Ventures1
- MRL Ventures Fund1
- Nextech Invest1
- Novo Holdings1
- Pappas Capital1
- Peak6 Strategic Capital1
- RA Capital Management1
- Samsara Biocapital1
- Schroder Adveq1
- Sound Bioventures1
- Surveyor Capital1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Immunos Therapeutics | Switzerland | 2 | €78M |
| Ambagon Therapeutics | Netherlands | 1 | €75M |
| Breye Therapeutics | Denmark | 1 | €68M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Ambagon Therapeutics | Series A | €75M | 2022-01 |
| Immunos Therapeutics | Series B | €68M | 2022-06 |
| Immunos Therapeutics | Series C | €9.9M | 2024-09 |